Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Bio    DIM   FR0013154002

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 01:05pm CEST
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SARTORIUS STEDIM BIO
04/19SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
04/07 SARTORIUS STEDIM BIO : ex-dividend day for annual dividend
04/04 SARTORIUS STEDIM BIOTECH SHS : Resolutions of the Annual Shareholders' Meeting o..
02/21 SARTORIUS STEDIM BIO : Resolutions by the Board of Directors
02/08 SARTORIUS STEDIM BIO : 2016 targets fully achieved; strong outlook for 2017
01/25SARTORIUS STEDIM BIOTECH SA : annual earnings release
01/14 SARTORIUS STEDIM BIOTECH : Opens A New Validation Service Laboratory At Its Shan..
2016 SARTORIUS STEDIM BIOTECH : launches two Single-use Sartocon Loop Assemblies
2016 SARTORIUS STEDIM BIO : Biotech Opens New Bioanalytical Testing Laboratory
2016SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
04/24 Sartorius Stedim Biotech reports Q1 results
04/03 MKS announces sale of data analytics solutions business
Advertisement
Financials (€)
Sales 2017 1 171 M
EBIT 2017 262 M
Net income 2017 183 M
Debt 2017 78,0 M
Yield 2017 0,72%
P/E ratio 2017 30,46
P/E ratio 2018 27,42
EV / Sales 2017 4,91x
EV / Sales 2018 4,45x
Capitalization 5 676 M
More Financials
Chart SARTORIUS STEDIM BIO
Duration : Period :
Sartorius Stedim Bio Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIO
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 67,0 €
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive Director & Executive VP-Operations
Oscar-Werner Reif Executive Director, EVP-Research & Development
Reinhard Vogt Executive Director, EVP-Marketing & Sales Services
Liliane de Lassus Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIO2.67%6 182
MEDTRONIC PLC16.65%113 741
BAXTER INTERNATIONAL I..25.58%30 176
ZIMMER BIOMET HOLDINGS..15.94%24 076
C R BARD INC36.86%22 267
HOYA CORPORATION8.19%18 604
More Results